Genetic overgrowth syndrome: A single center’s experience

Chong Kun Cheon1,*, Yoo-Mi Kim2, Ju Young Yoon1, and Young A Kim1

1Department of Pediatrics, Pusan National University Children’s Hospital, Pusan National University School of Medicine, Yangsan, Korea
2Department of Pediatrics, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea

Purpose: Overgrowth syndromes are conditions that involve generalized or localized areas of excess growth. In this study, the clinical, molecular, and genetic characteristics of Korean patients with overgrowth syndrome were analyzed.

Materials and Methods: We recruited 13 patients who presented with overgrowth syndrome. All patients fulfilled inclusion criteria of overgrowth syndrome. Analysis of the clinical and molecular investigations of patients with overgrowth syndrome was performed retrospectively.

Results: Among the 13 patients with overgrowth syndrome, 9 patients (69.2%) were found to have molecular and genetic causes. Among the seven patients with Sotos syndrome (SS), two had a 5q35 microdeletion that was confirmed by fluorescent in situ hybridization. In two patients with SS, intragenic mutations including a novel mutation, c.5993T>A (p.M1998L), were found by Sanger sequencing. One patient displayed overlapping clinical features of SS, a de novo heterozygous deletion in the chromosomal region 7q22.1-22.3 was found by single nucleotide polymorphism-based microarray.

Conclusion: Considering high detection rate of molecular and genetic abnormalities in this study, rigorous investigations of overgrowth syndrome may be an important tool for the early diagnosis and genetic counseling. A detailed molecular analysis of the rearranged regions may supply the clues for the identification of genes involved in growth regulation.

Key words: Growth, Sotos syndrome, Beckwith-Wiedemann syndrome, Early diagnosis.

Introduction

Overgrowth syndromes are a heterogeneous group of conditions characterized by either localized or generalized excessive growth for age and sex. Most overgrowth syndromes comprise a group of disorders associated with excessive growth and other features, such as facial dysmorphism, congenital anomalies, neurological problems and an increased risk of neoplasia [1]. Therefore, it is important to diagnose the overgrowth syndromes for accurate genetic counseling and to inform cancer surveillance and prognosis prediction. However, diagnostic categorization of these conditions is difficult because many have overlapping clinical features. Recent advances in understanding the genetic basis of overgrowth syndromes have resulted in a move...
away from clinical classification to molecular classification of overgrowth syndromes [2]. Despite these recent advances, the disease causing mechanism remains unknown in 20–40% of patients, underlining the genetic heterogeneity of these disorders [1]. Moreover, many patients with overgrowth syndromes do not belong to any recognizable condition and remain unexplained. In this study, we report 13 patients with overgrowth syndromes including recognizable overgrowth syndrome and unclassified overgrowth syndrome. In addition to their clinical relevance, our results emphasize the importance of a chromosomal imbalance in the etiology of unclassified overgrowth syndrome and may help to identify novel genes involved in growth anomalies.

Materials and Methods

1. Ethics statement
This study was performed in accordance with the Declaration of Helsinki. Appropriate institutional review board approval was obtained for this study from the Institutional Review Board at Pusan National University Yangsan Hospital (IRB no. 05-2018-069). Written informed consent was obtained from each participant before the collection of blood samples and subsequent analysis.

2. Study patients and molecular analysis
A total of 20 patients suspected of overgrowth syndrome visited to Pusan National University Children’s Hospital from March 2009 to March 2016. Among them, 13 patients (7 females and 6 males) were evaluated to identify the underlying causes of overgrowth syndrome and were enrolled in this study. Flow sheet showing a diagnostic approach to generalized overgrowth is depicted in Fig. 1. A loose criteria of overgrowth syndrome was used in this study because there might be considerable phenotypic and etiologic heterogeneity in this domain. For example, approximately 10% of the children with Sotos syndrome (SS) have a height <97th percentile [3]. A loose criteria includes height >95th percentile and/or head circumference >97th percentile, dysmorphic craniofacial features, and/or congenital anomalies. All patients fulfilled inclusion criteria of overgrowth syndrome. Clinical criteria of SS included a distinctive facial appearance (broad and prominent forehead, sparse frontotemporal hair, downslanting palpebral fissures, long and narrow face, long chin), developmental delay (DD), mild to severe intellectual disability (ID), and overgrowth (head circumference ≥2 standard deviation [SD] above the mean). For the diagnostic approach to SS, fluorescent in situ hybridization (FISH) study was initially performed on metaphase spreads of cultured peripheral leukocytes stimulated with phytohemagglutinin using an NSD1 probe (Vysis LSI NSD1; Abbott Laboratories, Chicago, IL, USA) on 5q35. If the FISH analysis revealed no deletion, NSD1 sequencing analysis was performed to identify intragenic mutations successively followed by multiplex ligation-dependent probe amplification (MLPA). All coding exons and exon-intron boundaries of the NSD1 gene were amplified by polymerase chain reaction (PCR) and a thermal cycler (Applied Biosystems, Foster City, CA, USA). Direct sequencing was done using a BigDye Terminator.

Fig. 1. Flow chart showing a diagnostic approach to generalized overgrowth. BWS, Beckwith-Wiedemann syndrome; FISH, fluorescent in situ hybridization; NGS, next generation sequencing; WES, whole exome sequencing; PCR, polymerase chain reaction; MLPA, multiplex ligation-dependent probe amplification.
Cycle Sequencing Ready Reaction kit (Applied Biosystems), and the analysis was performed using an ABI3130xl Genetic Analyzer (Applied Biosystems).

Cardinal features of Beckwith-Wiedemann syndrome (BWS) include macrosomia, macroglossia, hemihyperplasia, and ear creases/pits. Methylation analysis of the 2 imprinted domains at 11p15.5 (H19DMR and differentially methylated region of Kv [KvDMR]) was performed by methylation-specific PCR in the patients presenting with at least two features of BWS. When recognizable overgrowth syndrome such as SS and BWS were ruled out based on clinical assessment, we performed karyotyping/single nucleotide polymorphism (SNP)-based microarray (Affymetrix Cytoscan 750K array [Affymetrix, Santa Clara, CA, USA]) analysis as first step for unclassified overgrowth syndrome. Clinical manifestations, clinical courses, and results of molecular and genetic study were retrospectively reviewed.

Results

1. Auxological data and molecular analysis for patients with overgrowth syndrome

Thirteen patients were diagnosed with overgrowth syndrome during a period of seven years. Detailed demographics of the enrolled patients are presented in Table 1. Seven (53.8%) were female and six (46.2%) were male. The patients had mean±SD gestational age of 37.7±3.3 weeks (range, 30.6 to 43.0 weeks) and mean±SD birth weight standard deviation score of 0.002±0.001. Age at the time of overgrowth syndrome diagnosis was 30.2±24.0 months (range, 0.3 to 84.0 months). Among 13 patients, seven (53.8%) were diagnosed with SS followed by five (38.5%) patients with BWS, and one (7.7%) with 7q22.1-22.3 microdeletion. All cases were sporadic. Of these 13 patients, seven (53.8%) had more than 97th percentile height, six (46.1%) had more than 97th percentile body weight, and eight (61.5%) had more than 97th percentile head circumference at diagnosis. Among the seven patients with SS, two had a 5q35 microdeletion that was confirmed by FISH. A novel missense mutation, c.5993T>A (p.R1861L), and a nonsense mutation, c.5581C>T (p.R1861*), were found in two patients with SS by Sanger sequencing. One patient had one copy deletion of NDS1 gene including a small part of FGFR4 which was confirmed by MLPA. Two patients were diagnosed with probable SS without any mutation or deletion. Among five patients with BWS, three had aberrant imprinting control regions; 2 hypermethylation of the differentially methylated region of H19 (H19DMR), 1 hypomethylation of the KvDMR. Two patients were diagnosed with probable BWS without any abnormal methylation. In one patient showing normal karyotype of peripheral leukocytes, a de novo heterozygous 2.2 Mb deletion in the chromosomal region 7q22.1-22.3 was found by SNP-based microarray. The deletion started from 102,877,293 bp extending to 105,121,326 bp [Genomic build: Hg19]. The deleted region contains nine genes: PMPCB, DNAJC2, PSMD2, SLC26A5, RELN, ORC5L, LHFPL3, KMT2E, and SPRK2 (Fig. 2).

2. Clinical manifestations of patients with overgrowth syndrome

All of the patients suspected as overgrowth syndrome had excessive growth, facial dysmorphism, and congenital anomalies at the time of their clinic visit. Among the seven SS patients, three displayed scoliosis and had epilepsy that required anti-epileptic drug treatment (Fig. 3). Three patients had abnormal brain regions that included periventricular leukomalacia (PVL), microadenoma at the left lobe of the pituitary gland, cavum septum pellucidum, and ventriculomegaly. Two patients with SS had attention deficit hyperactivity disorder and renal anomaly including left renal pelviectasis and multicystic dysplastic kidney, respectively. One patient each had cardiac anomaly such as atrial septal defect (ASD), hyperinsulinemic hypoglycemia, and umbilical hernia. All patients with BWS had macroglossia. Among the five patients with BWS, three had hemihypertrophy which was left-side dominant, two patients had an umbilical hernia and hypoglycemia during infancy, respectively (Fig. 4). One patient with hypomethylation of KvDMR was diagnosed with central precocious puberty requiring gonadotropin releasing hormone agonist, complex partial seizure, PVL, and focal stenosis of the aqueduct. One patient with hypermethylation of H19DMR had left hepatoblastoma and renal anomaly that included renal pelviectasis. Finally, a 3-year-old-boy had 7q22.1-7q22.3 microdeletion. He was the second child of unrelated healthy parents of normal stature. Dysmorphic features included high and prominent forehead, hypertelorism, and small mouth. Other features noted included cryptorchidism, retractive testis, recurrent hypoglycemia during infancy, and DD. The patient displayed a vigorous appetite at one-year-of-age. Later, he developed severe obesity (body mass index >99th percentile). He began to walk unaided at 23-months-of-age and could only speak one word at 3-years-of-age. To date, at 3 years, his height, weight and head circumference are over 97th percentile. Bone age is advanced over chronological age by 6 months. Brain magnetic resonance imaging (MRI) revealed hypoplasia of the corpus callosum and cortical dysplasia.
Table 1. Clinical and molecular characteristics of patients with overgrowth syndrome

<table>
<thead>
<tr>
<th>Patient</th>
<th>K1</th>
<th>K2</th>
<th>K3</th>
<th>K4</th>
<th>K5</th>
<th>K6</th>
<th>K7</th>
<th>K8</th>
<th>K9</th>
<th>K10</th>
<th>K11</th>
<th>K12</th>
<th>K13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>4 yr</td>
<td>2 yr</td>
<td>7 yr</td>
<td>3 yr</td>
<td>4 yr</td>
<td>15 mon</td>
<td>79 day</td>
<td>75 day</td>
<td>4 yr</td>
<td>12 mon</td>
<td>84 day</td>
<td>3 yr</td>
<td></td>
</tr>
<tr>
<td>Current age (yr)</td>
<td>11.1</td>
<td>5.9</td>
<td>9.5</td>
<td>3.8</td>
<td>4.9</td>
<td>9.9</td>
<td>1.6</td>
<td>9.1</td>
<td>4.8</td>
<td>7.8</td>
<td>3.0</td>
<td>0.5</td>
<td>3.0</td>
</tr>
<tr>
<td>Gestational age (week+days)</td>
<td>41+2</td>
<td>40+5</td>
<td>43+0</td>
<td>39+0</td>
<td>39+1</td>
<td>38+0</td>
<td>36+0</td>
<td>36+2</td>
<td>37+3</td>
<td>30+6</td>
<td>37+2</td>
<td>33+0</td>
<td>39+0</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>4,530</td>
<td>3,660</td>
<td>3,200</td>
<td>3,730</td>
<td>4,560</td>
<td>3,000</td>
<td>3,440</td>
<td>4,400</td>
<td>1,610</td>
<td>3,460</td>
<td>2,190</td>
<td>3,650</td>
<td></td>
</tr>
<tr>
<td>Height at diagnosis (p)</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>95</td>
<td>&gt;97</td>
<td>95</td>
<td>&gt;97</td>
<td>95</td>
<td>&gt;97</td>
<td>95</td>
<td>95</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Body weight at diagnosis (p)</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>50-75</td>
<td>75</td>
<td>&gt;97</td>
<td>75</td>
<td>75-90</td>
<td>&gt;97</td>
<td>90</td>
<td>75</td>
<td>50</td>
<td>&gt;97</td>
<td></td>
</tr>
<tr>
<td>Head circumference at diagnosis (p)</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>&gt;97</td>
<td>50</td>
<td>75</td>
<td>75-90</td>
<td>75-90</td>
<td>50</td>
<td>&gt;97</td>
<td></td>
</tr>
<tr>
<td>DD/ID</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>HA</td>
<td>N</td>
<td>ASD</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>RA</td>
<td>MCDK</td>
<td>N</td>
<td>RP</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>RP</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>EP</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>SC</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>ADHD</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Brain MRI</td>
<td>nl</td>
<td>nl</td>
<td>MI,CSP</td>
<td>nl</td>
<td>nl</td>
<td>VM</td>
<td>PVL</td>
<td>nl</td>
<td>nl</td>
<td>PVL</td>
<td>nl</td>
<td>PVL</td>
<td>nl</td>
</tr>
<tr>
<td>Malignancy</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>HG during infancy</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HT</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y (Lt)</td>
<td>Y (Rt)</td>
<td>Y (Lt)</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>UA</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>CPP</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td>SS</td>
<td>SS</td>
<td>SS</td>
<td>SS</td>
<td>SS</td>
<td>SS</td>
<td>SS</td>
<td>SS</td>
<td>SS</td>
<td>BWS</td>
<td>BWS</td>
<td>BWS</td>
<td>BWS</td>
</tr>
<tr>
<td>Test method</td>
<td>MLPA</td>
<td>Seq/del/dup analysis</td>
<td>Seq analysis</td>
<td>FISH</td>
<td>Seq/del/dup analysis</td>
<td>FISH</td>
<td>Seq analysis</td>
<td>met-specific PCR</td>
<td>met-specific PCR</td>
<td>met-specific PCR</td>
<td>met-specific PCR</td>
<td>SNP-microarray</td>
<td></td>
</tr>
</tbody>
</table>

F, female; M, male; p, percentile; DD, developmental delay; ID, intellectual disability; Y, yes; N, no; HA, heart anomaly; ASD, atrial septal defect; RA, renal anomaly; MCDK, multicystic dysplastic kidney; RP, renal pelvisctasis; EP, epilepsy; SC, scoliosis; ADHD, attention deficit hyperactivity disorder; MRI, magnetic resonance imaging; nl, normal; MI, microadenoma; CSP, cavum septum pellucidum; VM, ventriculomegaly; PVL, periventricular leukomalacia; HB, hepatoblastoma; HG, hypoglycemia; HT, hemi-hypertrophy, Lt, left; Rt, right; UA, umbilical hernia; CPP, central precocious puberty; SS, Sotos syndrome; BWS, Beckwith-Wiedemann syndrome; microdel, microdeletion; MLPA, multiplex ligation-dependent probe amplification; Seq, sequencing; del, deletion; dup, duplication; FISH, fluorescent in situ hybridization; met, methylation; PCR, polymerase chain reaction; KvDMR, differentially methylated region of Kv; het, heterozygous.

*Novel mutation.
Discussion

This study analyzed the clinical and genetic features of 13 Korean patients with overgrowth syndrome. Among the 13 patients with overgrowth syndrome, 9 patients (69.2%) were found to have molecular and genetic causes for overgrowth syndrome. All the patients manifested the clinical features of overgrowth syndrome, which include height >95th percentile, dysmorphic craniofacial features, and other congenital anomalies. Overgrowth syndromes comprise a diverse group of clinically recognizable multiple congenital malformation syndromes [4]. Numerous multiple malformation syndromes associated with growth excess have been described. These pathologic syndromes share several characteristics, which include: overgrowth...
that is present at birth and persists into postnatal life, effects on both weight and length, and an associated with multiple characteristic anomalies and often with a neoplastic predisposition [5]. For some of overgrowth syndromes including SS, ID is a key feature, although a borderline or low-normal intellect is possible. In the present study, all patients with SS showed DD or ID while one patient with BWS displayed speech delay. It is important to note that some causes of overgrowth, macrosomia, tall stature, macrocephaly, or obesity are not seen in the context of syndromes. When intellect is normal, the most common causes of overgrowth are familial, growth acceleration driven by overnutrition (including infants of diabetic mothers), and endocrine conditions such as precocious puberty, hyperthyroidism, congenital adrenal hyperplasia, growth hormone-secreting adenoma, familial glucocorticoid deficiency, and aromatase deficiency [6].

The relatively prevalent overgrowth syndromes in fetuses and neonates include SS and BWS [7]. These syndromes are not associated with overproduction of growth hormone [7]. Children with SS have distinctive facial features such as macro dolichocephaly, marked frontal bossing, and a frontoparietal receding hairline. Just over 20% of patients with SS have congenital heart defects, usually a patent ductus arteriosus or ASD [8]. In the present study, 14.2% of patients with SS had ASD, which is consistent with previous reports. Renal abnormalities and scoliosis have also been frequently reported [9]. In our study, approximately 30% of patients with SS had renal abnormalities, such as multicystic dysplastic kidney and renal pelviectasis. SS is associated with dilatation of the cerebral ventricles and other brain formation abnormalities, including an absent corpus callosum, prominent cortical sulci, trigone, occipital horns, cavum septum pellucidum, and cavum velum interposition [8]. In this study, approximately 43% of patients displayed various brain formation abnormalities that include PVL, cavum septum pel- lucidum, ventriculomegaly, and brain tumor, such as microadenoma. In addition, approximately 40% of individuals with SS reportedly experience seizures [10], which is consistent with our study (42.8%).

Mutations in NSD1 are responsible for SS and found in approximately 80-90% of patients [9]. SS results from constitutional intragenic loss-of-function mutations, primarily truncating mutations [3]. Of interest, 5q35 microdeletions are more frequently detected in approximately 50% of Japanese patients with SS [11], whereas 5q35 microdeletions are uncommonly found less than 15% of patients in other areas of the world [3]. In a previous report of SS in Korea, approximately 50% of the patients had a 5q35 microdeletion [12], which is slightly higher than the present finding of approximately 30%. Of note, the c.5993T>A (p.M1998L) variant detected in the present study was a novel missense mutation. This region is highly conserved and this variant was not found in 1000 Genome Project, Exome Variant Server, Exome Aggregation Consortium, the dbSNP database. This variant was predicted to be deleterious through in silico analysis including SIFT (scale-invariant feature transform), polyphen-2, and Mutation taster. The patient showing this variant had intractable epilepsy and brain abnormalities such as pituitary microadenoma and cavum septum pellucidum in brain MRI. In patients with SS, brain tumors are rare. According to the large series of SS case, sacrococcygeal teratomas, presacral ganglieneuroma, neuroblastoma, and acute lymphocytic leukemia usually occurred in children with confirmed NSD1 mutation [13]. The c.5581C>T (p.R1861*) mutation was previously reported in 2007 [14]. The patient presented with recurrent hypoglycemic events during infancy due to hyperinsulinemic hypoglycemia, which necessitated diazoxide medication. Of interest, subject K1 had one copy deletion of NDS1 gene including FGFR4 gene. Taylor et al. [15] noted that FGFR4 is expressed in myoblasts during normal development and found that FGFR4 was significantly
sequencing is required in the patient because sequence analysis
However, the patient displayed severe obesity with hyperphagia,
high and prominent forehead, macrocephaly, and hypertelorism.

In the present study, overlapping clinical features of SS included
BWS [21].

Unfortunately, we could not find any abnormal methylation
methylation at H19DMR, one of whom had left hepatoblasto-

In the present study, two of five patients with BWS had a gain of
alterations and pUPD11 have the highest risk of tumor [18,20].
silencing of H19 expression [21]. Patients with IC1 methylation
ated with biallelic expression of insulin-like growth factor 2 and
gain of methylation on the maternal IC allele, which is associ-

In the present study, overlapped clinical features of SS included
high and prominent forehead, macrocephaly, and hypertelorism.
However, the patient displayed severe obesity with hyperphagia,
which is not consistent with the clinical manifestation of SS.
Therefore, chromosomal analysis was done as the initial diag-

Taking together, clinical perception and accurate phenotyping
should guide the diagnosis of more common syndromes, such as
BWS and SS. However, molecular genetic confirmation and
molecular classification is important, given the many types of
overgrowth syndromes and because the phenotypes often over-

BWS is characterized by macrosomia, asymmetric over-
growth, macroglossia, abdominal wall defects, hypoglycemia,
ear creases, visceromegaly, renal malformations, facial nevus
flameus, and embryonal tumors [16]. Children with BWS have
an increased risk (approximately 8.6%) of developing embryonal
tumors [17,18]. In the present study, one patient with BWS dis-
played hepatoblastoma stage II requiring left lobectomy. In BWS,
the tumor risk appears to be related to the underlying defect
[19]. Approximately 50% of patients with BWS have a loss of
methylation at IC2 (KvDMR1) [20]. Approximately 20% of BWS
cases have paternal uniparental disomy (pUPD) involving chro-
mosome 11p15 [11]. About 5–10% of patients with BWS have a
gain of methylation on the maternal IC allele, which is associ-
ated with biallelic expression of insulin-like growth factor 2 and
silencing of H19 expression [21]. Patients with IC1 methylation
alterations and pUPD11 have the highest risk of tumor [18,20].
In the present study, two of five patients with BWS had a gain of
methylation at H19DMR, one of whom had left hepatoblasto-

Table 2. Gene contents of the 7q22.1-22.3 deleted region

<table>
<thead>
<tr>
<th>Gene</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMPCB</td>
<td>Peptidase, mitochondrial processing, beta</td>
</tr>
<tr>
<td>DNAJC2</td>
<td>DNA/HSP40 Homolog, subfamily C, member 2</td>
</tr>
<tr>
<td>PSMC2</td>
<td>Proteasome 26S subunit, ATPase, 2</td>
</tr>
<tr>
<td>SLC26A5</td>
<td>Solute carrier family 25, member 5</td>
</tr>
<tr>
<td>RELN*</td>
<td>Reelin</td>
</tr>
<tr>
<td>ORC5L</td>
<td>Origin recognition complex, subunit 5, Saccharomyces cerevisiae, Homolog OF</td>
</tr>
<tr>
<td>LHFPL3a</td>
<td>Lipoma HMGIC fusion partner-like 3</td>
</tr>
<tr>
<td>KMT2</td>
<td>Histone-lysine N-methyltransferase 2</td>
</tr>
<tr>
<td>SRPK2a</td>
<td>Serine/threonine-protein kinase 2</td>
</tr>
<tr>
<td>HSP, heat shock protein; ATPase, adenosine triphosphase; HMGIC, high-mobility group protein isoform I-C.</td>
<td></td>
</tr>
<tr>
<td>aInvolved in the clinical phenotype of the patient.</td>
<td></td>
</tr>
</tbody>
</table>

Involved in the clinical phenotype of the patient.

overexpressed in rhabdomyosarcoma tumors of high metastatic
potential, and higher FGFR4 expression was associated with a
lower rate of survival. In this patient, tumor surveillance might
be important not only with respect to genetic counseling but
also appropriate medical management.

The central nervous system findings in our patient may be linked
to hemizygous loss of RELN activity.

The laminar organization of the cerebral cortex is regulated by Reelin and its receptors [25]. During ontogenesis of the human brain, Reelin is
synthesized in neurons at the telencephalic marginal zones and
other pioneer neurons, as well as by granule cells of the external
granular layer of the cerebellum [24]. The laminar organization
of the cerebral cortex is regulated by Reelin and its receptors [25].
The central nervous system findings in our patient may be linked
to hemizygous loss of RELN activity.
Acknowledgements

We thank our patient and her family members for their participation in this study. This study was supported by a 2017 research grant from Pusan National University Yangsan Hospital.

References